COMP <GO>
CLDX vs NTLA // EV/EBITDA & P/E VALUATION
Celldex Therapeutics Inc. (NASDAQ) VS. Intellia Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CLDX 3
— NTLA 3
■ METRIC PARITY
LAST: $29.89 (+0.78%) • MKT CAP: $2.35B
valuation
—
LAST: $13.23 (-0.68%) • MKT CAP: $1.85B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CLDX VS. NTLA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CLDX | NTLA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.10% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -9.10% | -21.35% | +12.25 | CLDX | /fcf-yield <GO> |
| Operating Margin | -60.00% | -60.00% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | -60.00% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | 16.90% | -81.90 | NTLA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 20.25 | 1.17 | +19.08 | CLDX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 4/9 | -1.00 | NTLA | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.5 | 53.4 | -7.99 | NTLA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.35B | $1.85B | $493.4M | CLDX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CLDX REV | NTLA REV | CLDX GROSS % | NTLA GROSS % | CLDX FCF | NTLA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.5M | $67.7M | 87.1% | — | -$213.7M | -$395.9M |
| FY 2024 | $7.0M | $57.9M | 97.2% | — | -$159.7M | -$354.7M |
| FY 2023 | $6.9M | $36.3M | — | — | -$107.3M | -$394.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CLDX // BETA —
NTLA // BETA —